Psoriasiform eruption on the face and extremities associated with nivolumab therapy

Nivolumab is an IgG4 anti–programmed cell death protein 1 monoclonal antibody, part of a newer class of drugs known as immune checkpoint inhibitors.1 Nivolumab has been approved for use in previously treated patients with non–small cell lung cancer, renal cell carcinoma, and metastatic melanoma and is in the advanced stages of development for the treatment of squamous cell carcinoma of the head and neck, urothelial cancer, gastric cancer, glioblastoma, and other lung cancers.1-3